Computer-guided methimazole dosing for Graves' disease
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a computer program called DigiThy that helps doctors adjust your methimazole dose compared to standard care. The goal is to control your thyroid hormone levels more effectively and safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have active Graves' disease with recent blood tests showing low TSH, high fT4, and positive TRAb antibodies.
- You should not have started antithyroid treatment yet, or have been taking it for less than 4 weeks, or had a relapse after stopping it for at least 4 weeks.
- You cannot have had radioactive iodine treatment before.
- You cannot be pregnant or planning pregnancy during the study.
- You cannot be taking propylthiouracil (a different antithyroid drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a wearable device called Glandy HYPER that helps doctors adjust your antithyroid medication dose for Graves' disease. It may offer a more precise and convenient way to manage your treatment.
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This study tests whether adding vitamin D therapy to the usual Graves' disease treatment (methimazole) can improve thyroid function and lower antibody levels in children. If your child is between 9 and 17 and recently diagnosed, they may be able to participate.
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
This study tests a new way to adjust thyroid medication doses for children with either congenital hypothyroidism or Graves' disease. It aims to help find the right dose more easily and improve treatment outcomes.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.